A20 as a Potential Therapeutic Target for COVID‐19
ABSTRACT Background Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is a major concern due to its astonishing prevalence and high fatality rate, especially among elderly people. Patients suffering from COVID‐19 may exhibit immunosuppre...
Saved in:
Main Authors: | Yongyao Wu, Lilan He, Rong Li, Jiuxuan Li, Qing Zhao, Bin Shao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Immunity, Inflammation and Disease |
Subjects: | |
Online Access: | https://doi.org/10.1002/iid3.70127 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunosuppressants in modern approaches to treatment of inflammatory bowel diseases
by: O. B. Schukina, et al.
Published: (2013-05-01) -
Comparative Analysis of AES, Blowfish, Twofish, Salsa20, and ChaCha20 for Image Encryption
by: Rebwar Khalid Muhammed, et al.
Published: (2024-05-01) -
Serum PM20D1 levels are associated with nutritional status and inflammatory factors in gastric cancer patients undergoing early enteral nutrition
by: Jin Zhengyu, et al.
Published: (2025-02-01) -
Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2025-02-01) -
cGAS-STING targeting offers therapy choice in lung diseases
by: Yu Wang, et al.
Published: (2025-02-01)